Simmons, Sean K.
Lithwick-Yanai, Gila
Adiconis, Xian
Oberstrass, Florian
Iremadze, Nika
Geiger-Schuller, Kathryn http://orcid.org/0000-0002-6705-0681
Thakore, Pratiksha I.
Frangieh, Chris J.
Barad, Omer
Almogy, Gilad
Rozenblatt-Rosen, Orit http://orcid.org/0000-0001-6313-3570
Regev, Aviv
Lipson, Doron
Levin, Joshua Z. http://orcid.org/0000-0002-0170-3598
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5RM1HG006193-09, R44HG010558, R44HG011060)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (5F32AI138458)
Howard Hughes Medical Institute
Klarman Cell Observatory, Broad Institute of MIT and Harvard
Broad Institute | Stanley Center for Psychiatric Research, Broad Institute
Klarman Cell Observatory, Broad Institute of MIT and Harvard
Article History
Received: 7 February 2022
Accepted: 1 August 2022
First Online: 15 September 2022
Competing interests
: A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and until July 31, 2020 was a member of the scientific advisory boards of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. From August 1, 2020, A.R. is an employee of Genentech, a member of the Roche Group and has equity in Roche. From November 16, 2020, K.G.S. is an employee of Genentech. From March 22, 2021, P.I.T. is an employee of Genentech. From October 19, 2020, O.R.R. is an employee of Genentech and has equity in Roche. O.R.R. is a co-inventor on patent applications filed by the Broad Institute for inventions related to single-cell genomics. She has given numerous lectures on the subject of single-cell genomics to a wide variety of audiences and, in some cases, has received remuneration to cover time and costs. G.L.Y., F.O, N.I., O.B., G.A. and D.L. are employees and shareholders of Ultima Genomics. The other authors declare that they have no competing interests.